ResearchAndMarkets.com has added its 2026 report on Alzheimer’s disease to its offering. The study assesses more than 200 companies and 240 marketed and investigational therapies, comparing assets by development stage, molecule type, route of administration, therapeutic approach and clinical status. Alzheimer’s disease is a progressive neurodegenerative disorder and the most common cause of dementia among adults aged 65 and older, with pathology associated with amyloid-beta plaques, tau tangles and neuronal degeneration. The report reviews symptomatic treatments including donepezil, rivastigmine and galantamine, as well as disease-modifying amyloid-targeting medicines for eligible patients with early disease and confirmed amyloid pathology. It covers marketed therapies such as Eli Lilly’s Kisunla and Eisai and Biogen’s LEQEMBI, alongside pipeline assets including AR1001, ACP-204, SAR448851, mivelsiran, HT-4253, ABBV-1758 and RG6627. The analysis also examines clinical trials, sponsor and geographic activity, inactive programs, unmet needs, collaborations, licensing agreements, acquisitions, regulatory developments and emerging technologies.